Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Artru

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 28, 2002
Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancerJ Taïeb, P Artru, B Baujat, et al.
British Journal of Cancer|April 20, 2006
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patientsM Mabro, P Artru, T André, et al.
La Revue De Medecine Interne|January 28, 2004
[Long term survival in metastatic colorectal cancer treated with leucovorin and 5-fluoro-uracil chemotherapy]N Perez, C Tournigand, M Mabro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinomaJ Taïeb, E Mitry, V Boige, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2006
FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II studyJ Taïeb, T Lecomte, T Aparicio, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2013
The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011A Lièvre, P Artru, M Guiu, et al.
Bulletin Du Cancer|May 14, 2009
First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II studyP Afchain, B Chibaudel, G Lledo, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2001
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)F Maindrault-Goebel, A de Gramont, C Louvet, et al.
British Journal of Cancer|October 17, 2003
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderlyT Aparicio, J Desramé, T Lecomte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2013
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trialF C Bidard, F Huguet, C Louvet, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|March 28, 2002
Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancerJ Taïeb, P Artru, B Baujat, et al.
British Journal of Cancer|April 20, 2006
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patientsM Mabro, P Artru, T André, et al.
La Revue De Medecine Interne|January 28, 2004
[Long term survival in metastatic colorectal cancer treated with leucovorin and 5-fluoro-uracil chemotherapy]N Perez, C Tournigand, M Mabro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinomaJ Taïeb, E Mitry, V Boige, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2006
FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II studyJ Taïeb, T Lecomte, T Aparicio, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2013
The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011A Lièvre, P Artru, M Guiu, et al.
Bulletin Du Cancer|May 14, 2009
First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II studyP Afchain, B Chibaudel, G Lledo, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2001
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)F Maindrault-Goebel, A de Gramont, C Louvet, et al.
British Journal of Cancer|October 17, 2003
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderlyT Aparicio, J Desramé, T Lecomte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2013
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trialF C Bidard, F Huguet, C Louvet, et al.
Pageof 4